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Abstract  
Bevacizumab is a monoclonal antibody that exerts its antitumor activity by inhibiting vascular 
endothelial growth factor (VEGF). Consequently, it suppresses endothelial cell proliferation, 
vascular permeability, and angiogenesis. This inhibitory effect contributes to tumor size 
reduction, but causes wound healing delay, specifically during the proliferative phase, in patients 
receiving bevacizumab. Although surgical wound healing complications associated with 
bevacizumab have been extensively reported, there is limited literature on peripheral wound 
healing complications. More importantly, histopathology of bevacizumab-associated wound 
healing complications has not been described. We present the histopathology findings of a non-
healing ulcer in a patient receiving bevacizumab, providing insight into the possible etiology of 
this drug adverse reaction. Furthermore, our patient’s positive response to hyperbaric oxygen 
suggests its possible use for treatment of bevacizumab associated non-healing wounds. 
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Introduction  
Bevacizumab is an angiogenesis inhibitor that targets the vascular endothelial growth factor A 
(VEGF-A) receptor. It was first approved in 2004 for treatment of metastatic colon cancer. Since 
then, bevacizumab has shown successful response in Kaposi sarcoma including AIDS associated 
disseminated form with resolution of lesion assessed histologically and by imaging.(1) It has also 
been used for various other cancers, including metastatic renal cell carcinoma, glioblastoma, and 
non-small cell lung cancer.(2) Bevacizumab’s inhibitory side effect on wound healing has been 
described for surgical wounds.(3, 4) However, non-surgical wound healing complications 
(WHC) have not been reported with detailed histopathology description. Herein, we present a 
case of a non-healing wound in a patient on long-term bevacizumab therapy with histopathology 
















A man in his 70s with a history of metastatic colorectal carcinoma on capecitabine and 
bevacizumab was referred to our clinic for a persistent painful ulcer on his right forearm.  The 
patient had no previous history of WHC. Eight months prior, the patient noticed a new purple 
lesion on his right forearm, which was painful and itchy with erosion and occasional bleeding. 
The patient saw a dermatologist four months after the appearance of the lesion as it failed to heal. 
A biopsy report described cutaneous ulcer with no further specification. The biopsy site did not 
heal, and he continued to experience worsening pain for four months. By then, he had been 
treated with topical mupirocin and clindamycin, intralesional triamcinolone, oral doxycycline, 
and oral minocycline with no improvement in pain or size of the ulcer. Subsequently, the patient 
was referred to our clinic to exclude pyoderma gangrenosum. At presentation to our clinic, there 
was a 2.5x1.5cm ulcer with undermining borders and purulent discharge (Fig 1). Bacterial 
culture was positive for Corynebacterium species, which was treated with cephalexin, 
polymyxin-bacitracin ointment and silver sulfadiazine. Upon follow-up visits, the ulcer remained 
and a greenish discharge from the ulcer was noted. Bacterial culture grew Pseudomonas 
aeruginosa, for which the patient was treated with topical gentamicin ointment. When no sign of 
infection was seen at the follow-up visit, intralesional triamcinolone 5mg/mL injection and 
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clobetasol ointment were given. Nonetheless, the ulcer persisted, with minimal improvement in 
size and pain level.  
Biopsy slides showed a failure of wound healing with improper re-epithelialization and 
insufficient connective tissue regeneration to fill the underlying dermis without inflammation 
(Fig 2). The likely cause of the non-healing ulcer was discerned to be the current treatment with 
bevacizumab, which is known to interrupt surgical wound healing in patients with tumor 
resection.(3) However, after discussion with the patient’s oncologist regarding this concern, the 
decision was made to continue bevacizumab, as the patient’s cancer was controlled on 
bevacizumab and capecitabine. The patient was referred to a wound care clinic for consideration 
of hyperbaric treatment that significantly improved the wound healing process and the wound 

















Bevacizumab is often used as the adjuvant or neoadjuvant treatment of various cancers, 
including metastatic colorectal cancer, metastatic renal cell carcinoma, glioblastoma, and non-
small cell lung cancer.(2) The antibody, by inhibiting the role of VEGF, can cause severe wound 
healing delay. VEGF has been shown to mediate endothelial-cell-induced coagulation and 
angiogenic activity during the proliferative phase of wound healing.(5) In fact, surgical WHCs 
that include dehiscence, surgical site bleeding and infection are well-documented adverse 
reactions of bevacizumab.(3, 4) Given these complications, it is recommended that bevacizumab 
is stopped at least 60 days before surgery and restarted 28 days after surgery. 
However, non-surgical WHC has limited descriptions in the literature, although a few 
animal studies have reported peripheral skin WHC in rabbits with short-term exposure to 
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intravitreal bevacizumab.(5, 6) An initial study observing cutaneous wound healing following 
intravitreal bevacizumab demonstrated reduced neovascularization one week following treatment 
compared with untreated controls.(6) Further characterization of wound margins after 
bevacizumab treatment revealed significantly diminished wound tensile strength in treated 
groups compared with control.(5)   
The histopathology behind bevacizumab-associated WHC has only been described in 
animal models and briefly in human patients. Histopathologic examination in animal studies has 
focused on quantifying blood vessel development in anti-VEGF treated groups, revealing 
diminished numbers of endothelial cells.(5) In one human presentation, histopathology of 
bevacizumab associated skin necrosis showed vascular thrombosis and infarction of dermal and 
subdermal layers.(7)  
Our cases’ histopathology findings present the lack of dermal regeneration in patients on 
bevacizumab along with the lack of re-epithelialization on the surface. During wound healing, 
neovascularization during the proliferative phase of wound healing promotes cell proliferation 
and adhesion that compose the dermal matrix.(8) Given that angiogenesis is disrupted with 
bevacizumab therapy, dermal matrix regeneration is expected to be diminished, as seen in our 
patient’s histopathology (thin to absent dermis with exposing the subcutaneous fat). As a result, a 
lack of fibrosis for wound healing and insufficient dermal matrix regeneration are expected. 
Subsequently, in the lack of fibrosis, the fibroblast derived keratinocyte growth factor, the major 
stimulator of basal keratinocyte proliferation during wound repair, is presumably reduced.(9) 
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This is consistent with the lack of basal keratinocytes and disrupted re-epithelialization in our 
patient. Thus, it appears that the defective angiogenesis leading to the lack of dermis 
regeneration and re-epithelialization hindered wound healing in our patient.  
 
Hyperbaric oxygen (HBO) has been an effective adjuvant treatment in various wounds 
including non-healing diabetic and venous insufficiency ulcers, thermal burns and infected 
wounds.(10) Given our patient’s persistent ulcer, HBO was attempted. It is known that oxygen 
supply to ischemic wounds accelerates wound healing by upregulating growth cytokines, such as 
fibroblast growth factor and VEGF.(11) Moreover, HBO has resulted in modest effects on 
angiogenesis and a VEGF abundance in wounds following therapy.(11) Despite our patient’s 
improvement with HBO, the exact mechanism leading to healing of bevacizumab associated 
WHC is not described yet. However, it can be considered for wounds secondary to bevacizumab 
therapy. 
The clinical course of the patient highlights how important it is for dermatologists to be 
aware of bevacizumab and its association with peripheral WHC to prevent any unnecessary work 
up and further morbidities in patients on bevacizumab with non-healing ulcers. From the positive 
outcome of our patient’s wound, hyperbaric oxygen treatment may be considered for the similar 
cases. Additional studies are needed to further characterize the mechanism of bevacizumab-
associated WHC. 
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Abbreviations and Acronyms:  
HBO: hyperbaric oxygen 
VEGF: vascular endothelial growth factor 
VEGF-A: vascular endothelial growth factor A 
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Figure 1. Bevacizumab-associated wound healing failure. 2.5 x 1.5cm punched out ulcer is 
seen with undermining borders and purulent discharge on the right dorsal mid-forearm. 
Figure 2. Histopathology of bevacizumab-associated wound healing complication. A, At 
lower magnification (H&E, 20X), the ulceration is not associated with appropriate dermal 
connective tissue regeneration and the subcutaneous fat is pushing into the reticular dermis. B, 
At higher magnification (H&E, 40X), there is a lack of re-epithelization on the edge of the 
ulceration and lack of vascularization on the base of the ulceration.   
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Key Messages:  
• Bevacizumab therapy inhibits angiogenesis and can lead to non-surgical wound 
healing complications  
• An examination of histopathology reveals diminished dermal regeneration and 
surface re-epithelialization, providing a possible etiology for bevacizumab’s 
effect on wound healing 
• An awareness about this presentation can prevent unnecessary workup and 
appropriate treatment for patients 
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